Trials / Completed
CompletedNCT03147183
Kinetic Study of CD8+ CMV-specific Cellular Immunity in Renal Transplant Patients After Receiving Thymoglobulin
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 150 (actual)
- Sponsor
- Maimónides Biomedical Research Institute of Córdoba · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Renal transplant candidates who have CMV-specific, CD8+ T-cells, are CMV-seropositive and carry HLA-A1 and/ or HLA- A2 alleles have a high probability to maintain this type of immunity during the three first months after the transplant, despite induction immunosuppressive therapy (thymoglobulin).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Thymoglobulin | This study will use non-probability, convenience sampling from patients kidney transplants who receive induction immunosuppressive therapy with thymoglobulin |
Timeline
- Start date
- 2016-08-09
- Primary completion
- 2018-10-31
- Completion
- 2019-10-21
- First posted
- 2017-05-10
- Last updated
- 2021-07-20
Locations
1 site across 1 country: Spain
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03147183. Inclusion in this directory is not an endorsement.